Evidence map›Paper›PMID 25598841›Full record

ArticleFibrogenesis & tissue repair2015

Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices.

Satish Kumar Sadasivan, Nethra Siddaraju, Khaiser Mehdi Khan, Balamuralikrishna Vasamsetti, Nimisha R Kumar, Vibha Haridas, Madhusudhan B Reddy, Somesh Baggavalli, Anup M Oommen, Raghavendra Pralhada Rao

Open access · hybridAbstract read
In one paragraph

Article in Fibrogenesis & tissue repair, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Best Practices and Progress in Precision-Cut Liver Slice Cultures.International journal of molecular sciences · 2021
    Review
  6. Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds.American journal of physiology. Gastrointestinal and liver physiology · 2019
    Article
  7. Article
  8. Article
  9. Effect of ginseng extract on the TGF-β1 signaling pathway in CClBMC complementary and alternative medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Satish Kumar Sadasivan *Connexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Nethra Siddaraju *Connexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Khaiser Mehdi KhanConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Balamuralikrishna VasamsettiConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Nimisha R KumarConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Vibha HaridasConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Madhusudhan B ReddyConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Somesh BaggavalliConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Anup M OommenConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Raghavendra Pralhada RaoConnexios life sciences private limited, No-49, Shilpa vidya, 1st Main, 3rd phase, J P nagara, Bangalore, 560078 India.
Connexios (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrecision-cut liver slices present different cell types of liver in a physiological context, and they have been explored as effective in vitro model systems to study liver fibrosis. Inducing fibrosis in the liver slices using toxicants like carbon tetrachloride is of less relevance to human disease conditions. Our aim for this study was to establish physiologically relevant conditions in vitro to induce fibrotic phenotypes in the liver slices.

resultsPrecision-cut liver slices of 150 μm thickness were obtained from female C57BL/6 J mice. The slices were cultured for 24 hours in media containing a cocktail of 10 nM each of TGF-β, PDGF, 5 μM each of lysophosphatidic acid and sphingosine 1 phosphate and 0.2 μg/ml of lipopolysaccharide along with 500 μM of palmitate and were analyzed for triglyceride accumulation, stress and inflammation, myofibroblast activation and extracellular matrix (ECM) accumulation. Incubation with the cocktail resulted in increased triglyceride accumulation, a hallmark of steatosis. The levels of Acta2, a hallmark of myofibroblast activation and the levels of inflammatory genes (IL-6, TNF-α and C-reactive protein) were significantly elevated. In addition, this treatment resulted in increased levels of ECM markers - collagen, lumican and fibronectin.

conclusionsThis study reports the experimental conditions required to induce fibrosis associated with steatohepatitis using physiologically relevant inducers. The system presented here captures various aspects of the fibrosis process like steatosis, inflammation, stellate cell activation and ECM accumulation and serves as a platform to study the liver fibrosis in vitro and to screen small molecules for their antifibrotic activity.

Indexed as

FibrosisLiver sliceMyofibroblastScreening platformStellate cells

Identifiers

PMID25598841
PMCPMC4296550
OpenAlexW2141534736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.